Genetic determinants of drug response in heart failure.
Heart failure management is complex and costly. Genetic variations that alter drug absorption, metabolism, and receptor-ligand interactions have the potential to modify drug response and safety. Evidence shows that genetic factors interact with numerous heart failure medications, including vasodilators, beta blockers, and angiotensin-converting enzyme inhibitors. Technologic advances will soon allow population-based genome-wide genetic testing at a reasonable cost. Understanding the genetic factors that influence drug response in heart failure will allow physicians to personalize therapies and optimize response while minimizing serious adverse events.
Lowes
Brian D
BD
Division of Cardiology, Campus Box B130, University of Colorado Health Sciences Center, Aurora, CO 80045, USA. Brian.Lowes@UCHSC.edu
Buttrick
Peter M
PM
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology; D054316:Biomarkers, Pharmacological; D004077:Digoxin / Q000494:pharmacology; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D043922:Toxicogenetics
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D054316:Biomarkers, Pharmacological; D004077:Digoxin